MIRA Pharmaceuticals, Inc.
MIRAAnalyst Consensus
Rating Trend
Earnings History
Next report: Dec 2, 2026 · EPS est. $-0.03| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.03 | — | — | — |
| May 14, 2026 | $-0.03 | — | — | — |
| Mar 31, 2026 | $-0.15 | $-0.04 | — | — |
| Nov 13, 2025 | $-1.18 | $-1.18 | — | — |
| Aug 14, 2025 | $-0.09 | $-0.11 | — | — |
| May 14, 2025 | $-0.11 | $-0.15 | — | — |
| Mar 28, 2025 | $-0.15 | $-0.29 | $11.2M | — |
| Nov 12, 2024 | $-0.14 | $-0.18 | — | — |
News
MIRA reports significant weight and fat reduction with oral SKNY-1 in obese mice, with favorable lean-mass and weight-regain outcomes versus semaglutide.
MIAMI, Oct. 22, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapies for neurologic, inflammatory and metabolic disorders, today announced positive results from a 21-day preclinical proof-of-concept study evaluating oral MIRA-55 in a validated model of chronic inflammatory pain. The results support the continued advancement of MIRA-55 toward an Investigational New Drug (IND) submissio…
MIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced that, following review and comments from the U.S. Food and Drug Administration (FDA), the Phase 2a protocol evaluating Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) has been submitted for Institutional Review Board (IRB) review at a leading cancer research institut…
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2026) - Miravalles Gold Corp. (CSE: MIRA) (OTC Pink: SSRSF) (the "Company" or "Miravalles") announces the filing of an independent technical report for its Fairfield Gold Project (the "Project") in Nayarit, Mexico. The report, titled Technical Report on the Fairfield Gold Project, has an effective date of July 31, 2026, and was prepared by Warren Robb, P.Geo.
MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive results from completed 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs.